… , and molecular characteristics of SARS-CoV-2. We summarize the … of SARS-CoV-2,
which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV…

… to discontinue the dose escalation, to lower the dose, or to continue with the next dose group.
The maximum tolerated dose (MTD) was defined as the highest dose of SCTA01 at which …

… different strategies employed in SARS-CoV-2 vaccine development, … 1 dose-escalation
studies assessing prime and boosting at 28 days with 2, 4 and 8 µg doses, showed all doses to …

… formulated mRNA vaccine encoding the trimeric SARS-CoV-2 spike protein receptor …
dose-escalation phase 1 studies of 18–55 year-old healthy adults, randomized to receive 2 doses …

… to receive 3 doses of 5 μg or 10 μg of a SARS-CoV-2 inactivated vaccine, or placebo separated
by 28 days. Adverse events (AEs) were recorded through day 28 after each dosing. Live …

… We performed a randomized, placebo-controlled Phase I trial with an unblinded dose
escalation and a double-blind treatment phase at 2 sites in France and Belgium to evaluate the …

… postulated as having a pathophysiologic role in coronavirus disease 2019 (COVID-19)
associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In …

… dosing was performed in each dose-escalation cohort. Progression in that cohort and dose
escalation … Participants received a BNT162b2 priming dose on day 1, and a booster dose on …

… The current randomized, double-blind, placebo-controlled, single-dose escalation Phase
1 study investigated the safety, tolerability, immunogenicity, and PK of MW33 in healthy …

… considered a high risk also for SARS-CoV-2 infection 12,13 . … -dose, dose-escalation
study to evaluate the safety, pharmacokinetics, and virus neutralization titers of the anti-SARS-CoV-…